The global market for Losartan Potassium, a widely used antihypertensive drug, is set to experience a significant price decline in December 2024, driven by a confluence of market dynamics including softening demand, stable manufacturing output, and favorable supply chain conditions. Additionally, market participants are expected to clear out older inventories as the year ends, further contributing to the downward pressure on Losartan Potassium prices.

One of the key factors behind this price drop of Losartan Potassium is the improvement in production capacity. Data from China’s National Bureau of Statistics (NBS) reveals that the country’s manufacturing Purchasing Managers' Index (PMI) reached 50.3 in November, up from 50.1 in October, indicating a steady expansion in the manufacturing sector. As China is a major exporter of Active Pharmaceutical Ingredients (APIs), this increase in manufacturing output is expected to result in an oversupply relative to demand, pushing Losartan Potassium prices downward globally.

Furthermore, a surge in China’s economic activity, fueled by recent stimulus measures, is also having a significant impact. These policies are slowly filtering through the economy, promoting industrial growth and stabilizing production. However, just as this stimulus begins to take effect, geopolitical tensions are intensifying. U.S. trade threats, particularly the potential for additional tariffs on Chinese goods, could disrupt the recovery of China’s industrial sector. If implemented, these tariffs could weaken demand from the U.S. market and exacerbate the downward pressure on Losartan Potassium prices.

In Europe, economic conditions are similarly contributing to a reduction in Losartan Potassium prices. Germany’s economic downturn deepened in November, with business activity falling for the fifth consecutive month at its fastest pace since February. This weakening economic environment, coupled with high inflation in the Eurozone, is prompting more cautious consumer sentiment. Data from Eurostat showed that consumer price inflation in the 20 countries using the euro rose to 2.3% in November, higher than the previous month’s 2.0%, which is above the European Central Bank’s 2% target. This acceleration in inflation, combined with expectations of a more cautious interest rate cut by the European Central Bank, is likely to keep consumer spending subdued, further reducing demand for Losartan Potassium.

ChemAnalyst forecasts that Losartan Potassium prices will likely continue to decline, driven mainly by persistently low demand from end-user sectors. The ongoing global economic uncertainties are causing consumers to be more cautious with their spending, which is expected to further dampen demand for the Losartan Potassium. As both businesses and consumers adapt to the current economic challenges, this cautious sentiment may keep prices of Losartan Potassium relatively low in the near future.